Verified factor-similar pair

IJR vs JSMD

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
81
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IJR has the higher backtested relative Sharpe (0.980 vs 0.885).
  • IJR has the lower published fee (0.06% vs 0.30%).
  • JSMD is cheaper on dividend valuation (95 vs 110, where 100 is each fund's historical median).
  • IJR has the stronger regression fit (adjusted R-squared 0.968 vs 0.920).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IJR

iShares Core S&P Small Cap ETF
SMB
Adj. R2
0.968
Rel. Sharpe
0.980
Mkt beta
0.99
AUM
US$96.8B
MER
0.06%
Valuation
110

JSMD

Janus Henderson Small/Mid Cap Growth Alpha ETF
SMB
Adj. R2
0.920
Rel. Sharpe
0.885
Mkt beta
1.05
AUM
US$879M
MER
0.30%
Valuation
95

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IJR
+0.84
|t|
+36.0
JSMD
+0.64
|t|
+10.0
diff +0.19
HML
IJR
+0.20
|t|
+8.3
JSMD
-0.02
|t|
-0.3
diff +0.22
RMW
IJR
+0.13
|t|
+4.8
JSMD
+0.01
|t|
+0.1
diff +0.12
CMA
IJR
-0.02
|t|
-0.4
JSMD
-0.13
|t|
-1.6
diff +0.12
UMD
IJR
+0.03
|t|
+2.4
JSMD
+0.10
|t|
+2.1
diff -0.07

Why This Pair Matches

Exposure level
77
Exposure shape
97
Mkt beta diff
0.06
Rel. Sharpe diff
0.096

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IJR fund page JSMD fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.